Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Job Harenberg

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Thrombosis Research|April 13, 2016
Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patientsJob Harenberg
Thrombosis Research|May 2, 2006
Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancyJob Harenberg
Medizinische Klinik (Munich, Germany : 1983)|October 11, 2003
[Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage]Job Harenberg
Current Opinion in Pulmonary Medicine|August 13, 2002
Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosisJob Harenberg
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 17, 2011
Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonizationJob Harenberg
Thrombosis Research|January 26, 2011
Overview on guidelines and recommendations for generic low-molecular-weight heparinsJob Harenberg
Expert Review of Clinical Pharmacology|November 25, 2011
Idraparinux and idrabiotaparinuxJob Harenberg
Seminars in Thrombosis and Hemostasis|February 14, 2009
Development of new anticoagulants: present and futureJob Harenberg
Seminars in Thrombosis and Hemostasis|September 30, 2009
New anticoagulants in atrial fibrillationJob Harenberg
Thrombosis and Haemostasis|November 6, 2009
Development of idraparinux and idrabiotaparinux for anticoagulant therapyJob Harenberg
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Thrombosis Research|April 13, 2016
Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patientsJob Harenberg
Thrombosis Research|May 2, 2006
Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancyJob Harenberg
Medizinische Klinik (Munich, Germany : 1983)|October 11, 2003
[Treatment of thrombosis with low-molecular-weight heparin. Comparison of body weight-adjusted and fixed dosage]Job Harenberg
Current Opinion in Pulmonary Medicine|August 13, 2002
Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosisJob Harenberg
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 17, 2011
Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonizationJob Harenberg
Thrombosis Research|January 26, 2011
Overview on guidelines and recommendations for generic low-molecular-weight heparinsJob Harenberg
Expert Review of Clinical Pharmacology|November 25, 2011
Idraparinux and idrabiotaparinuxJob Harenberg
Seminars in Thrombosis and Hemostasis|February 14, 2009
Development of new anticoagulants: present and futureJob Harenberg
Seminars in Thrombosis and Hemostasis|September 30, 2009
New anticoagulants in atrial fibrillationJob Harenberg
Thrombosis and Haemostasis|November 6, 2009
Development of idraparinux and idrabiotaparinux for anticoagulant therapyJob Harenberg
Pageof 11